Abbott’s received FDA EUA for laboratory PCR assay that detects and differentiates SARS-CoV-2, Flu A, Flu B and RSV
On Mar. 5, 2021, Abbott announced FDA Emergency Use Authorization (EUA) for the company’s Alinityﾙ m Resp-4-Plex molecular…
Altasciences announced phase I research for COVID-19 pneumonia treatment
On Mar. 3, 2021, Altasciences announced support for ReAlta Life Sciences’ Phase I trial to evaluate RLS-0071 for…
First identification of human cases of avian influenza A(H5N8) infection
On Feb. 26, 2021, Russian authorities reported the detection of influenza A(H5N8) virus infection in seven poultry workers…
NIH study sIntranasal influenza vaccine spurred strong immune response in Phase 1 study
On Feb. 3, 2021, an experimental single-dose, intranasal influenza vaccine, was safe and produced a durable immune response…
CDC study showed 2019-20 flu vaccine effectively prevented hospitalizations and emergency visits in children
On Jan. 27, 2021, a CDC study found that the 2019-2020 flu vaccine provided significant protection against flu-associated…
Rocheﾒs Xofluza approved by the EC for treatment of influenza, first new influenza antiviral in almost 20 years
On Jan. 11, 2021, Roche announced that the European Commission (EC) had approved Xofluzaﾮ (baloxavir marboxil) for the…
Biotechnology | COVID-19 | HIV | Influenza | Life Science News | Vaccine
Moderna announced three new development programs in infectious disease vaccines
On Jan. 11, 2021, Moderna announced that it was expanding its pipeline of innovative vaccines with three new…
Twist Bioscience supplied Centers for Disease Control and Prevention with custom SARS-CoV-2 synthetic RNA controls
On Jan. 7, 2021, Twist Bioscience announced it will supply the U.S. Centers for Disease Control and Prevention…
Quidel received Emergency Use Authorization for QuickVue SARS rapid antigen test for COVID-19 diagnosis
On Dec. 21, 2020, Quidel announced that it had received Emergency Use Authorization from the FDA to market…
Mount Sinai researchers advanced universal influenza virus vaccine
On Dec. 7, 2020, an universal influenza virus vaccine, which produces antibodies that target the part of the…
FDA authorized first COVID-19 and flu combination test for use with home-collected samples
On Dec. 4, 2020, the FDA authorized the first diagnostic test for at home collection of patient samples…
High-dose influenza vaccine showed no additional benefit for heart disease patients
On Dec. 4, 2020, it was reported in JAMA that high-dose influenza (commonly known as flu) vaccines are…
Roche announced FDA approval of Xofluza for prevention of influenza following contact with infected person
On Nov. 24, 2020, Roche announced that the FDA had approved a supplemental New Drug Application for Xofluzaﾮ…
FDA expanded approval of influenza treatment to post-exposure prevention
On Nov. 23, 2020, the FDA expanded the approved indication for Genentech’s Xofluza (baloxavir marboxil) to include post-exposure…
Genentech announced FDA Approval of Xofluza for prevention of influenza following contact with infected person
On Nov. 23, 2020, Genentech announced that the FDA had approved a supplemental New Drug Application (sNDA) for…
XBiotech data showed effective anti-virus activity for antibodies in candidate influenza-COVID-19 therapeutic
On Nov. 19, 2020, XBiotech announced data for its breakthrough candidate therapy for treating infections of influenza and…
Celdara Medical secured funding to develop an adjuvanted universal flu vaccine
On Nov. 17, 2020, Celdara Medical announced that the NIH had awarded a two-year Small Business Innovation Research…
Aegis Sciences launched combined test for SARS-CoV-2 and influenza A/B virus
On Nov. 16, 2020, Aegis Sciences announced that it had launched a combined test for SARS-CoV-2 and influenza…
CHMP recommended EU approval of Rocheﾒs Xofluzaﾮ (baloxavir marboxil) for the treatment of influenza
On Nov. 13, 2020, Roche announced that the European Medicines Agencyﾒs (EMA) Committee for Medicinal Products for Human…
Mesa Biotech received additional $13 million from HHS to develop 30 minute SARS-CoV-2 & Flu A/Flu B test
On Nov. 6, 2020, Mesa Biotech announced it had been awarded a contract up to $13 million from…
Novavax announced facility expansion to support global vaccine development
On Oct. 30, 2020, Novavax announced the expansion of its Maryland campus to accommodate the companyﾒs rapid growth…
PerkinElmer received CE Mark for multi-analyte respiratory panel including COVID-19
On Oct. 26, 2020, PerkinElmer announced that its PKampﾙ Respiratory SARS-CoV-2 RT-PCR Panel had received clearance to be…
OPKO Health’s BioReference Laboratories launched multiplex COVID-19 and influenza A/B test
On Oct. 20, 2020, BioReference Laboratories, an OPKO Health company, announced that it was accepting specimens for a…
University of Oxford scientists developed extremely rapid diagnostic test for Covid-19
On Oct. 15, 2020, scientists from the University of Oxford ﾒs Department of Physics announced they had developed…
Vaxxas announced $22 million award from U.S. Government to advance Vaxxas Needle-Free HD-MAPﾙ vaccine patch
On Oct. 5, 2020, Vaxxas announced a $22 million United States government award to support the deployment of…
Quidel received Emergency Authorization for rapid antigen ‘ABC test’ assay for Influenza A+B and COVID-19
On Oct. 2, 2020, Quidel announced that it had received Emergency Use Authorization from the FDA to market…
Amyris delivered sustainable alternative to shark squalene adjuvant enabling vaccines with no sharks killed
On Oct. 1, 2020, Amyris announced that it has begun delivering samples to pharmaceutical companies of a sustainable…
Quest Diagnostics launched three new combined COVID-19 and respiratory virus tests
On Sept. 30, 2020, Quest Diagnostics announced three different test options for healthcare providers across the U.S.to aid…
BD announced CE Mark of portable, rapid point-of-care antigen test to detect SARS-CoV-2 in 15 minutes
On Sept. 30, 2020, BD (Becton, Dickinson) announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the…
XBiotech to develop human antibody combination as candidate treatment for influenza-COVID-19 co-infection
On Sept. 21, 2020, XBiotech announced it was developing a new breakthrough candidate therapy it calls FLUVIDﾙ for…